-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – (Riboflavin + Sodium Iodide) in Keratoconus
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - (Riboflavin + Sodium Iodide) in Keratoconus report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. (Riboflavin + Sodium Iodide) in Keratoconus Drug Details: A fixed-combination...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – (Decitabine + Tetrahydrouridine) in B-Cell Non-Hodgkin Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - (Decitabine + Tetrahydrouridine) in B-Cell Non-Hodgkin Lymphoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. (Decitabine + Tetrahydrouridine) in B-Cell Non-Hodgkin Lymphoma Drug Details:...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Triplex in Mantle Cell Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Triplex in Mantle Cell Lymphoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Triplex in Mantle Cell Lymphoma Drug Details: Triplex is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – KITE-718 in Refractory Acute Myeloid Leukemia
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - KITE-718 in Refractory Acute Myeloid Leukemia report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. KITE-718 in Refractory Acute Myeloid Leukemia Drug Details: KITE-718...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – VMD-928 in Colon Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - VMD-928 in Colon Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. VMD-928 in Colon Cancer Drug Details: VMD-928 is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – (Decitabine + Tetrahydrouridine) in Sickle Cell Disease
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. (Decitabine + Tetrahydrouridine) in Sickle Cell Disease Drug Details: Decitabine in combination with tetrahydrouridine is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – LYL-845 in Metastatic Melanoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - LYL-845 in Metastatic Melanoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. LYL-845 in Metastatic Melanoma Drug Details: LYL-845 is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Lemzoparlimab in Primary Mediastinal B-Cell Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Lemzoparlimab in Primary Mediastinal B-Cell Lymphoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Lemzoparlimab in Primary Mediastinal B-Cell Lymphoma Drug Details: TJC-4...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – EPI-589 in Parkinson’s Disease
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - EPI-589 in Parkinson's Disease report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. EPI-589 in Parkinson's Disease Drug Details: EPI-589 (PTC-589) is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – LYL-132 in Non-Small Cell Lung Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. LYL-132 in Non-Small Cell Lung Cancer Drug Details: LYL-132 is under development for the treatment...